Goserelin_acetate: profile and news

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
...powder), RHINOCORT AQUAĀ® (budesonide), SEROQUELĀ® (quetiapine fumarate), TOPROL-XLĀ® (metoprolol succinate), ZOLADEXĀ® (goserelin acetate implant), ZOMIG ... - Yahoo! News (press release)

AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005
...powder), RHINOCORT AQUA(R) (budesonide), SEROQUEL(R) (quetiapine fumarate), TOPROL-XL(R) (metoprolol succinate), ZOLADEX(R) (goserelin acetate implant), ZOMIG(R ... - PR Newswire (press release),

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
...powder), RHINOCORT AQUAĀ® (budesonide), SEROQUELĀ® (quetiapine fumarate), TOPROL-XLĀ® (metoprolol succinate), ZOLADEXĀ® (goserelin acetate implant), ZOMIG ... - Yahoo! News (press release)

AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005
...powder), RHINOCORT AQUA(R) (budesonide), SEROQUEL(R) (quetiapine fumarate), TOPROL-XL(R) (metoprolol succinate), ZOLADEX(R) (goserelin acetate implant), ZOMIG(R ... - PR Newswire (press release),

Other information

Indication
Breast cancer; Prostate carcinoma; Endometriosis

Pharmacology
The pharmacokinetics of ZOLADEX have been determined in both male and female healthy volunteers and patients. In these studies, ZOLADEX was administered as a single 250ęg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.

Mechanism Of Action
ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.

Drug Category
Antineoplastic Agents; Unclassified Therapeutic Agents (92:00.00); ATC:L02AE03

Brand Names/Synonyms
Goserelin acetate; Goserelin acetate (JAN/USP); Zoladex

Dosage Forms
supplied as a sterile and totally biodegradable D,L-lactic and glycolic acids copolymer (13.3-14.3 mg/dose) impregnated with goserelin acetate equivalent to 3.6 mg of goserelin in a disposable syringe device fitted with a 16-gauge hypodermic needle

Absorption
inactive orally, rapidly absorbed following subcutaneous administration

Interactions
No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs

Chemical IUPAC Name
N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-(carbamoylaminocarbamoyl)pyrrolidin-1-yl]carbonyl-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-tert-butoxy-ethyl]carbamoyl]-2-(4-hydroxyphenyl)-ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide

Chemical Formula
C59H84N18O14

Half Life
4-5 hours

Drug Type
Approved Drug

# Accession No
BIOD00113

CAS Registry Number
65807-02-5